GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

Figure 2: BCR-ABL contributes to differentiation arrest ... It seems likely that microarray gene-expression profiling will continue to identify many candidate genes. The next challenge is ...

ABL has data showing that ABL301 can penetrate ... as well as a now-defunct alliance between AbbVie and Voyager in 2019, based on gene therapy approaches to target the rogue protein.

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal focuses on developing neurodegenerative disease treatments.

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...